The prostacyclin pathway is among the 3 therapeutic pathways for the treatment of PAH1-3
Targeting multiple pathogenic
pathways is now standard of care4
- Endothelin pathway1
- Nitric oxide pathway2
- Prostacyclin pathway3
Overproduction of endothelial vasoconstrictors, such as endothelin-1, and underproduction of vasodilators, such as nitric oxide and prostacyclin, are associated with PAH3,5,6
Orenitram is an oral prostacyclin-class therapy7

How Orenitram’s mechanism of action targets 3 of the pathologic changes that occur in PAH3,7
Vasoconstriction
Orenitram directly dilates pulmonary and systemic arterial vascular beds
Platelet aggregation
Orenitram inhibits platelet aggregation
Smooth muscle proliferation
Orenitram inhibits smooth muscle cell proliferation